Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial

Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET, a targeted radiopharmaceutical for patients with unresectable or metastatic neuroendocrine tumors (NETs). Presented at the 2025 ASCO Annual Meeting, the updated data include follow-up on nine original patients and safety findings from 33 additional patients, totaling 42 treated participants.

A scientist in a lab analyzing a culture of cells affected by tumor immune evasion.

The therapy continues to show a strong safety profile, with no dose-limiting toxicities, no discontinuations due to adverse events, and no Grade 4 or 5 treatment-related adverse events. Most side effects were mild and unrelated to the drug, and no serious renal complications were reported.

Efficacy data are also promising: three out of seven patients in the higher-dose cohort had confirmed objective tumor responses, with one new response pending confirmation. Seven of nine patients from the initial cohorts remained free from disease progression after more than a year. These results support [212Pb]VMT-α-NET as a potentially important new option for NET patients. Perspective Therapeutics, Inc. (NYSE:CATX) will discuss these findings in a webcast on June 2 and plans further updates as the study progresses and additional data mature.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.